

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Flannery et al.

Serial No: 09/463,844

Filed: February 1, 2000

For: ZGGBP1, Novel Peptides Related to
Bipolar Affective Disorders Type I,
Sequences and Uses Thereof

Attorney Docket No. ASZD-P01-251

Art Unit: 1646

Examiner: O. Chernyshev

Assistant Commissioner of Patents
Washington, D.C. 20231

Declaration Under 35 U.S.C. §1.132 of Angela Flannery

Sir:

I, Angela Flannery of 22 River Street, Wilmslow, Cheshire, SK9 4AB, ENGLAND
hereby declare as follows:

1. I am a Senior Group Leader for AstraZeneca and am co-inventor of the abovedescribed application which teaches and claims ZGGBP1 polypeptides and methods for the detection thereof.
2. Experiments were performed under my direction to associate a single nucleotide polymorphism (SNP) in the ZGGBP1 gene (depicted in Exhibit A attached hereto) with one or more psychiatric conditions.
3. Three hundred patients diagnosed with bipolar affective disorder were tested for the presence of the SNP. Our statistical analysis of the results showed that the occurrence of the SNP of ZGGBP1 was strongly correlated with bipolar affective disorder ($p=0.0003$).
4. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code and that willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Angela Flannery

Dated: 12/1/03

Signature: Angela Flannery